At a glance
ClinicalIndex Comparison RecordN/ACompleted· 7 enrolled
Drug / intervention
cholecalciferol (Vitamin D3)dietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis
In Brief
A clinical study evaluating cholecalciferol (Vitamin D3) for Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis. Completed, enrolled 7 participants across 2 sites.
Detailed Summary
The purpose of this study is to see if giving people with CF and ABPA enough vitamin D to make their blood levels of the vitamin higher, will reduce the allergic response in their body and make the symptoms caused by ABPA better.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedOct 2010
Primary CompletionSep 2013
TodayJul 2026
First PostedOct 18, 2010
Enrollment StartSep 1, 2010
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 15.7 years ago
Interventions
cholecalciferol (Vitamin D3)dietary
4,000 IU of cholecalciferol (Vitamin D3) orally every day for six months